August 2014 Br J Cardiol 2014;21:103
BJCardio Staff and others
Lowering LDL-cholesterol: we need to do better It is essential that high-risk patients attain the recommended low-density lipoprotein (LDL)-cholesterol target. As reported at the first late-breaking session, the choice and dose of statin are key factors influencing LDL-cholesterol lowering. In a meta-analysis of the VOYAGER (Individual Patient Data Meta-analysis of Statin Therapy in At-risk Groups: Effects of Rosuvastatin, Atorvastatin and Simvastatin) database of 37 studies of high-intensity statins, 71% of patients treated with rosuvastatin 40 mg achieved at least 50% reduction in LDL-cholesterol levels, compared with 59% for atorvastatin 8
October 2013 Br J Cardiol 2013;20:130–2
BJCardio Staff and others
PRAMI: preventive PCI of other lesions beneficial in STEMI Patients undergoing percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) have better outcomes if non-culprit lesions are also treated, according to results from the PRAMI (Preventive Angioplasty in Myocardial Infarction Trial) study published recently in the New England Journal of Medicine (http://dx.doi.org/10.1056/NEJMoa1305520). In the trial, patients who also had PCI of the non-culprit lesions had a 65% reduction in event rate, driven by reductions in subsequent myocardial infarction (MI) and refractory angina. Presenting the results, Dr David Wa
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits